The National Institutes of Health (NIH) conducted a study to assess the safety of Redsiway in COVID-19 pregnancy patients

A new study funded by the National Institutes of Health (NIH) will assess the effects of remdesivir on COVID-19 pregnant women.
study, which will be conducted at 17 clinical sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects.
Ana W. Bianchi, director of the National Institute of Child Health and Human Development (NICHD) at NIH Eunice Kennedy Shriver, said: "There is an urgent need to identify effective treatments for this population and to determine whether Redsyves is suitable for use during pregnancy."
the study was co-funded by NICHD, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH).
study, called IMPAACT 2032, will be conducted by the International Network of Clinical Trials on Maternal, Child and Adolescent AIDS (IMPAACT) funded by the National Institutes of Health (NIH).
, originally developed to treat Ebola and Marburg virus infections, has been shown to accelerate the recovery of patients with COVID-19 in a clinical trial funded by NIAID.
, Redsiway has been approved by the U.S. Food and Drug Administration to treat COVID-19 in adults and children over 12 years of age.